R&D Why I'm focused on the trillion-dollar AMR crisis everyone's... AMR demands sustained commitment beyond conventional market incentives.
R&D When is the superbug message going to bite? As existing antibiotics become less effective, we edge closer to a future where routine infections & minor injuries could once again become high risk.
News Shionogi puts up to $600m behind BioVersys antibiotics Shionogi has added to its antibiotics pipeline by taking an option on a preclinical-stage candidate from BioVersys for non-tuberculous mycobacteria.
News Wockhardt has high hopes for novel antibiotic Zaynich Wockhardt has completed a pre-filing meeting with the FDA and is preparing to submit its novel antibiotic Zaynich in the US and Europe.
News Data sets up filing of new GSK antibiotic this year GSK has said it will file its oral carbapenem antibiotic tebipenem HBr for approval before the end of this year as a treatment for complicated UTIs.
Market Access Reuters Europe 2025: Using value propositions to improve acc... In a Reuters Pharma Europe 2025 fireside chat, NICE Advice Director Brad Grove spoke with Novartis's Matic Meglic about novel pharma payment models.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.